---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-107614"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2024-09-18T23:59:59+00:00"
generated_at: "2026-05-31T04:00:01.607054+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tivic Health receives IRB approval from Feinstein Institutes for ncVNS optimization study

## Summary
- Received IRB approval from Feinstein Institutes for clinical optimization study of ncVNS; enrollment to commence.
- Study will optimize stimulation parameters and electrode positioning using physiological measurements.
- Data will guide selection of clinical populations and design of future disease-specific trials.
- Collaboration with Fletcher Spaght to identify high-unmet-need clinical applications for ncVNS.
- Global VNS market valued at $8.59B (2021), projected $21.3B by 2030, CAGR 10.6%.

## SEC filing metadata
- accession: 0000950170-24-107614
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2024-09-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017024107614/0000950170-24-107614-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017024107614/tivc-20240918.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-107614
- JSON: https://secwatch.observer/filing/0000950170-24-107614.json
- Plain text: https://secwatch.observer/filing/0000950170-24-107614.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.